Details for New Drug Application (NDA): 020326
✉ Email this page to a colleague
The generic ingredient in NEUTREXIN is trimetrexate glucuronate. There is one drug master file entry for this compound. Additional details are available on the trimetrexate glucuronate profile page.
Summary for 020326
| Tradename: | NEUTREXIN |
| Applicant: | Medimmune Oncology |
| Ingredient: | trimetrexate glucuronate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020326
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 25MG BASE/VIAL | ||||
| Approval Date: | Dec 17, 1993 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 200MG BASE/VIAL | ||||
| Approval Date: | Jul 31, 1998 | TE: | RLD: | No | |||||
Expired US Patents for NDA 020326
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | ⤷ Get Started Free | ⤷ Get Started Free |
| Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-002 | Jul 31, 1998 | ⤷ Get Started Free | ⤷ Get Started Free |
| Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | ⤷ Get Started Free | ⤷ Get Started Free |
| Medimmune Oncology | NEUTREXIN | trimetrexate glucuronate | INJECTABLE;INJECTION | 020326-001 | Dec 17, 1993 | ⤷ Get Started Free | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
